Top Markets
Coin of the day
Q BioMed Inc. Q BioMed Inc.

Q BioMed Inc.

QBIO
주식 순위 #41615
Q BioMed Inc. functions as a biomedical accelerator and developer, actively... Q BioMed Inc. functions as a biomedical accelerator and developer, actively licensing, acquiring, and supplying resources to firms within the life sciences and healthcare sectors. Its commercial portfolio includes Metastron (Strontium Chloride SR89), a radiopharmaceutical designed to alleviate pain associated with metastatic bone cancer. Additionally, Q BioMed is advancing a pipeline of therapeutic candidates, including Man-01, a pre-clinical compound aimed at primary open-angle glaucoma; QBM-001, intended for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, which targets liver cancer. The company also collaborates with Mannin Research Inc. on the development of treatments for conditions such as acute respiratory distress syndrome, glaucoma, and various kidney diseases. Incorporated in New York, New York, in 2013, the entity was initially named ISMO Tech Solutions, Inc. before adopting its current name, Q BioMed Inc., in July 2015.
주가
$0.0001
마지막 동기화: 2026-04-02
시가총액
$14.51K
변동 (1일)
0.00%
변동 (1년)
9,900.00%
국가
US
거래 Q BioMed Inc. (QBIO)

카테고리

Q BioMed Inc. (QBIO)의 P/B 비율
2026 기준 P/B 비율 TTM: 0
Q BioMed Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 0입니다. 2026년 말 기준 P/B 비율은 0였습니다.
Q BioMed Inc.의 P/B 비율 기록 (2026 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/B 비율
회사 P/B 비율 P/B 비율 차이 국가
6.2613 -
US
6.3483 -
NL
- -
CH
3.634 -
BE
- -
KR